Want to see COCP full AI Analyst Report?
Cocrystal Pharma (COCP) Ratios
Cocrystal Pharma Ratios
COCP's free cash flow for Q2 2026 was $-2.52M. For the 2026 fiscal year, COCP's free cash flow was increased by $0.00 and operating cash flow was $-2.52M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.68 | 4.77 | 8.92 | 33.04 | 38.40 |
| Quick Ratio | 3.68 | 4.77 | 8.92 | 33.04 | 38.40 |
| Cash Ratio | 3.18 | 4.06 | 8.08 | 30.55 | 38.00 |
| Solvency Ratio | -2.50 | -4.42 | -3.65 | -30.36 | -7.59 |
| Operating Cash Flow Ratio | -3.71 | -6.79 | -4.50 | -17.63 | -8.23 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 4.75M | $ 7.65M | $ 24.22M | $ 38.91M | $ 57.48M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.13 | 0.06 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.24 | 0.19 | 0.07 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.19 | 0.16 | 0.07 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.53 | 1.41 | 1.18 | 1.03 | 1.02 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -8976.00 | -3507.75 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -19414.50 | -3555.25 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.13 | 0.18 | 0.19 | 0.04 | 0.07 |
| Net Debt to EBITDA | 0.65 | 0.46 | 1.17 | 2.05 | 4.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.92% | 97.91% | 96.90% | 100.02% | 99.75% |
| Return on Assets (ROA) | -90.93% | -130.08% | -57.53% | -95.10% | -17.87% |
| Return on Equity (ROE) | -139.49% | -183.81% | -68.16% | -98.16% | -18.29% |
| Return on Capital Employed (ROCE) | -120.22% | -162.11% | -66.29% | -97.99% | -18.27% |
| Return on Invested Capital (ROIC) | -115.10% | -157.81% | -65.73% | -97.40% | -18.21% |
| Return on Tangible Assets | -90.93% | -130.08% | -57.53% | -95.10% | -23.52% |
| Earnings Yield | -79.90% | -85.17% | -108.34% | -244.58% | -23.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 5.68 | 8.13 | 12.41 | 20.18 | 15.21 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -64.26 | -44.89 | -29.40 | -18.09 | -23.99 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 64.26 | 44.89 | 29.40 | 18.09 | 23.99 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -1.62 | -1.52 | -2.63 | -1.65 |
| Free Cash Flow Per Share | -0.73 | -1.62 | -1.53 | -2.64 | -1.66 |
| Dividend Paid and CapEx Coverage Ratio | -682.67 | -2060.63 | -124.29 | -289.66 | -244.60 |
| Capital Expenditure Coverage Ratio | -682.67 | -2060.63 | -124.29 | -289.66 | -244.60 |
| Operating Cash Flow Coverage Ratio | -5.44 | -9.13 | -7.91 | -72.17 | -23.82 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -74.22% | -80.25% | -89.06% | -135.46% | -21.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.26 | -1.17 | -0.92 | -0.41 | -4.23 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.75 | 2.16 | 0.63 | 0.40 | 0.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.35 | -1.25 | -1.12 | -0.74 | -4.70 |
| Price-to-Operating Cash Flow Ratio | -1.35 | -1.25 | -1.13 | -0.74 | -4.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.00 | 0.01 | -0.00 | 0.53 |
| Enterprise Value Multiple | -0.65 | -0.72 | 0.38 | 1.17 | -0.13 |
| Enterprise Value | 5.53M | 12.50M | -7.90M | -20.97M | 1.80M |
| EV to EBITDA | -0.65 | -0.72 | 0.38 | 1.17 | -0.13 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.67 | -0.76 | 0.53 | 0.97 | -0.14 |
| EV to Operating Cash Flow | -0.68 | -0.76 | 0.54 | 0.98 | -0.14 |
| Tangible Book Value Per Share | 0.56 | 0.94 | 2.73 | 4.86 | 7.60 |
| Shareholders’ Equity Per Share | 0.56 | 0.94 | 2.73 | 4.86 | 10.09 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.78 | -1.72 | -1.86 | -4.77 | -1.84 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.85 | 2.14 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.93 | 0.94 | 0.82 | 0.55 | 0.90 |
Currency in USD
